Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.35 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 5/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | BLM | P54132 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GMNN | O75496 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL180144 | 1.00 | TSHR (0.53) | TSHRLMNACYP1A2TDP1KMT2A | |
| SCHEMBL97780 | 0.97 | TSHR (0.56) | TSHRLMNACYP1A2TDP1KMT2A | |
| SCHEMBL163253 | 0.88 | TSHR (0.72) | TSHRLMNACYP1A2TDP1KMT2A | |
| SCHEMBL5067235 | 0.88 | TSHR (0.48) | TSHRLMNACYP1A2TDP1KMT2A | |
| SCHEMBL14235175 | 0.86 | TSHR (0.46) | TSHRLMNACYP1A2TDP1KMT2A | |
| SCHEMBL6548055 | 0.85 | TSHR (0.43) | TSHRLMNACYP1A2TDP1KMT2A | |
| SCHEMBL19308751 | 0.84 | — | — | |
| SCHEMBL16358111 | 0.82 | — | — | |
| SCHEMBL3078846 | 0.81 | TSHR (0.45) | TSHRLMNACYP1A2TDP1KMT2A | |
| SCHEMBL14042508 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1492554-B1 | SPHERICAL PROTEIN PARTICLES | ALTHEA TECH INC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-20160346350-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A BONE CONDITION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-12-01 | — | — | US | disclosed |
| US-9310379-B2 | Methods of crystallizing antibodies | AJINOMOTO ALTHEA, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| WO-2015116853-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A BONE CONDITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-08-06 | — | — | WO | disclosed |
| EP-2478005-B1 | PROTEIN A CRYSTALS AND CROSS-LINKED CRYSTALS AND METHODS OF USE THEREOF | AJINOMOTO ALTHEA INC (US) | 2014-11-12 | — | — | EP | disclosed |
| US-8558048-B2 | Stabilized protein crystals, formulations comprising them and methods of making them | ALTHEA TECHNOLOGIES, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120282464-A1 | Spherical Protein Particles and Methods of Making and Using Them | ALTHEA TECHNOLOGIES, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-7998477-B2 | spherical nanocrystalline composite particles or crystalline SPPs; protein is an antibody or FV fragment; tumor antigens, cardiovascular disorders, respiratory system disorders, transplant rejection, anticarcinogenic agents, antiinflammatory agents, radioimmunotherapeutic agents | ALTHEA TECHNOLOGIES INC. (US) | 2011-08-16 | — | — | US | disclosed |
| EP-2325205-A2 | Crystals of whole antibodies and fragments thereof and methods for making and using them | Altus Pharmaceuticals Inc. (US) | 2011-05-25 | — | — | EP | disclosed |
| EP-2267122-A1 | Controlled dissolution crosslinked protein crystals | Altus Pharmaceuticals Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| US-20030017144-A1 | Lipase-containing composition and methods of use thereof | ALTUS BIOLOGICS INC. | 2003-01-23 | — | — | US | disclosed |
| WO-2003000014-A2 | SPHERICAL PROTEIN PARTICLES AND METHODS OF MAKING AND USING THEM | ALTUS BIOLOGICS, INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| EP-1261368-A2 | LIPASE-CONTAINING COMPOSITION AND METHODS OF USE THEREOF | Altus Biologics Inc. (US) | 2002-12-04 | — | — | EP | disclosed |
| US-20020137156-A1 | CONTROLLED DISSOLUTION CROSSLINKED PROTEIN CRYSTALS | ALTUS PHARMACEUTICALS INC. | 2002-09-26 | — | — | US | disclosed |
| US-20020136719-A1 | Crystals of whole antibodies and fragments thereof and methods for making and using them | AJINOMOTO ALTHEA INC. | 2002-09-26 | — | — | US | disclosed |
| WO-2002072636-A2 | CRYSTALS OF WHOLE ANTIBODIES AND FRAGMENTS THEREOF AND METHODS FOR MAKING AND USING THEM | ALTUS BIOLOGICS INC. (US) | 2002-09-19 | — | — | WO | disclosed |
| US-20020045582-A1 | STABILIZED PROTEIN CRYSTALS FORMULATIONS CONTAINING THEM AND METHODS OF MAKING THEM | AJINOMOTO ALTHEA INC. | 2002-04-18 | — | — | US | disclosed |
| US-20010046493-A1 | Lipase-containing composition and methods of use thereof | ALTUS PHARMACEUTICALS, INC. | 2001-11-29 | — | — | US | disclosed |
| WO-2001062280-A2 | LIPASE-CONTAINING COMPOSITION AND METHODS OF USE THEREOF | ALTUS BIOLOGICS, INC. (US) | 2001-08-30 | — | — | WO | disclosed |
| US-6140475-A | REACTING A SLURRY OF PROTEIN CRYSTALS WITH MULTIFUNCTIONAL CROSSLINKING AGENT SUCH AS GLUTARALDEHYDE AT A CONCENTRATION OF 0.0076 TO 0.5 PERCENT BASED ON VOLUME; CAN BECOME SOLUBLE AND ACTIVE ON CHANGE IN ENVIRONMENT SUCH AS TEMPERATURE, PH | ALTUS BIOLOGICS INC. (US) | 2000-10-31 | — | — | US | disclosed |